Results 81 to 90 of about 1,231 (164)

Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes. [PDF]

PLoS ONE, 2017
Streptococcus pyogenes (group A streptococcus, GAS) is responsible for a wide array of infections. Respiratory transmission via droplets is the most common mode of transmission but it may also infect the host via other routes such as lesions in the skin.
Rasmus Mortensen, Dennis Christensen, Lasse Bøllehuus Hansen, Jan Pravsgaard Christensen, Peter Andersen, Jes Dietrich   +5 more
doaj   +1 more source

Optimisation of a murine splenocyte mycobacterial growth inhibition assay using virulent Mycobacterium tuberculosis

Scientific Reports, 2017
In the absence of a validated correlate of protection or robust animal models for human tuberculosis, Mycobacterial growth inhibition assays (MGIAs) aim to assess vaccines ability to inhibit mycobacterial growth in-vitro.
Christina Jensen, Line Lindebo Holm, Erik Svensson, Claus Aagaard, Morten Ruhwald   +4 more
doaj   +1 more source

Th1/Th17 T cell Tissue-Resident Immunity Increases Protection, But Is Not Required in a Vaccine Strategy Against Genital Infection With Chlamydia trachomatis

Frontiers in Immunology, 2021
The requirement for vaccine-induced tissue-resident immunity for protection against one or repeated infections with Chlamydia trachomatis (C.t.) is still not fully resolved.
Nina Dieu Nhien Tran Nguyen, Safia Guleed, Anja Weinreich Olsen, Frank Follmann, Jan Pravsgaard Christensen, Jes Dietrich   +5 more
doaj   +1 more source

Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation

Vaccine, 2015
CD4(+) T-cell priming is an essential step in vaccination due to the key role of T helper cells in driving both effector and memory immune responses. Here we have characterized in C57BL/6 mice the T helper subtype differentiation among tetramer-specific CD4(+) T cells primed by subcutaneous immunization with the tuberculosis vaccine antigen H56 plus ...
Prota, Gennaro, Christensen, Dennis, Andersen, Peter, Medaglini, Donata, Ciabattini, Annalisa   +4 more
openaire   +4 more sources

Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant [PDF]

, 2013
A broad coverage influenza vaccine against multiple viral strains based on the viral nucleoprotein (NP) is a goal pursued by many laboratories. If the goal is to formulate the vaccine with recombinant NP it is essential to count on adjuvants capable ...
Alvarez, Paula, Boado, Lorena Analía, Cargnelutti, Diego Esteban, Mattion, Nora Marta, Sanchez, María Victoria, Scodeller, Eduardo   +5 more
core  

A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8+ T Cells [PDF]

, 2016
The most effective strategy for protection against intracellular infections such as Leishmania is vaccination with live parasites. Use of recombinant proteins avoids the risks associated with live vaccines. However, due to low immunogenicity, they fail
A Brave, A Homhuan, A Pashine, A Rodriguez, A Sexton, AL Ackerman, B Guy, C Trumpfheller, C Watts, CR Casella, D Yang, DL Daleke, DM Smith, EJ Feldman, EM Agger, F Sallusto, I Mellman, IM Hafez, J Davidsen, JA Hubbell, JA Villadangos, JE Boudreau, JJ Moon, K Inaba, K Jain, K Kataoka, KD Lee, KK Peachman, KS Korsholm, L Flatz, L Kedzierski, L Krishnan, L Krishnan, L Leserman, L Van Kaer, MD Joshi, MJ Heffernan, OH Lowry, OP Joffre, P Bryant, P Nordly, R Ravindran, RA Schwendener, RM Steinman, RM Straubinger, S Bhowmick, S Nair, S Sinha, SA Plotkin, SG Reed, SG Reed, SR Cardoso, T Mazumdar, T Nakamura, V Mata-Haro, VP Torchilin, Y Tanaka   +56 more
core   +1 more source

Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis. [PDF]

PLoS ONE, 2016
The search for new and improved tuberculosis (TB) vaccines has focused on IFN-γ both for selecting antigens and for evaluating vaccine delivery strategies.
Rolf Billeskov, Esterlina V Tan, Marjorie Cang, Rodolfo M Abalos, Jasmin Burgos, Bo Vestergaard Pedersen, Dennis Christensen, Else Marie Agger, Peter Andersen   +8 more
doaj   +1 more source

Modulation of primary immune response by different vaccine adjuvants

Frontiers in Immunology, 2016
Adjuvants contribute to enhancing and shaping the vaccine immune response through different modes of action. Since the primary immune response can influence the overall quality of the response generated, here we investigate early biomarkers of ...
Annalisa Ciabattini, Elena Pettini, Fabio Fiorino, Gabiria Pastore, Peter Andersen, Gianni Pozzi, Donata Medaglini   +6 more
doaj   +1 more source

Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis

Frontiers in Immunology, 2017
There is an unmet need for a vaccine to control Chlamydia trachomatis (C.t.) infections. We have recently designed a multivalent heterologous immuno-repeat 1 (Hirep1) vaccine construct based on major outer membrane protein variable domain (VD) 4 regions ...
Anja Weinreich Olsen, Emma Kathrine Lorenzen, Ida Rosenkrands, Frank Follmann, Peter Andersen   +4 more
doaj   +1 more source

Engineering synthetic vaccines using cues from natural immunity [PDF]

, 2013
Vaccines aim to protect against or treat diseases through manipulation of the immune response, promoting either immunity or tolerance. In the former case, vaccines generate antibodies and T cells poised to protect against future pathogen encounter or ...
Irvine, Darrell J, Swartz, Melody A., Szeto, Gregory   +2 more
core   +2 more sources